Allergan CEO opposes fundamental shift in strategy, shares dip

Allergan CEO opposes fundamental shift in strategy, shares dip

FILE PHOTO: A sign marks Allergan's offices in Medford, Massachusetts, U.S., July 31, 2017. REUTERS/Brian Snyder/File Photo
REUTERS: Allergan Plc's chief executive on Monday said he was opposed to fundamental changes to the drug company's business strategy, even as its board considers drastic moves like splitting the company, selling off assets or doing deals to turn around a steep drop in its share price.Botox maker Allergan's shares fell 2.2 percent to US$158.42 in early trading on Monday. They have lost more than a third of their value over the last year.The company announced a strategic review of its business earlier this year. Allergan has hired multiple advisers, CEO Brent Saunders said on a conference call following the company's quarterly earnings. It is considering five options: deploying capital to buy back shares, doing divestitures, splitting the company, making acquisitions, or continuing to operate Allergan as is.Investors hoping for a major shift in strategy may be disappointed."Running the company in large part as it exists today is not only an option, but also the baseline against which all options need to be considered," Saunders said on the call, noting that his preliminary view was that a fundamental shift was unnecessary. "We're not going to execute an activity that doesn't recognize the full inherent value of our assets at Allergan."Allergan did not bid for Shire Plc earlier this month, after confirming reports that it considered an offer for the rare-disease treatment specialist.
Saunders said in an interview that large transformational deals are a "very low priority and a very unlikely outcome" of the review.BETTER-THAN-EXPECTED EARNINGSAllergan reported a better-than-expected first quarter profit and raised its full-year earnings forecast, driven by higher sales of its medical aesthetics products including blockbuster wrinkle treatment Botox.Sales of Botox, its biggest drug by revenue, jumped 14.5 percent to US$817.3 million in the quarter.
The company's aesthetics unit posted a near 30 percent jump in sales.U.S. Sales of Allergan's eye drug, Restasis, which is expected to face competition from cheaper drugs, fell 17.2 percent.The company now expects 2018 adjusted earnings of US$15.65 to US$16.25 per share, slightly above its previous forecast of US$15.25 to US$16 per share.Its net loss was US$332.5 million, or 99 cents per share, compared with US$2.63 billion, or US$7.86 per share, a year earlier.Excluding one-time items, Allergan reported a profit of US$3.74 per share, topping analysts' average expectation of US$3.36, according to Thomson Reuters I/B/E/S.Total revenue rose 2.8 percent to US$3.67 billion, topping analysts' average estimate of US$3.59 billion.(Reporting by Michael Erman in New York and Manas Mishra in Bengaluru; Editing by Anil D'Silva and Sai Sachin Ravikumar)
Source: Reuters
 Source : http://www.channelnewsasia.com/news/business/allergan-ceo-opposes-fundamental-shift-in-strategy--shares-dip-10189702